Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
AIMM Therapeutics, a therapeutic antibody company, today announced the appointments of Bob Löwenberg, MD, PhD, John Mendelsohn, MD, and Hidde Ploegh, Ph.D. to the company’s Scientific Advisory Board (SAB).
AIMM’s SAB oversees the company’s therapeutic antibody pipeline, including antibody target identification and validation, second generation antibody formats, and selection of candidate therapeutic antibodies for preclinical development and clinical proof of concept studies. AIMM-therapeutics is currently expanding its programs in the areas of cancer and autoimmune- and inflammatory diseases.
Help employers find you! Check out all the jobs and post your resume.
AIMM Therapeutics, a therapeutic antibody company, today announced the appointments of Bob Löwenberg, MD, PhD, John Mendelsohn, MD, and Hidde Ploegh, Ph.D. to the company’s Scientific Advisory Board (SAB).
AIMM’s SAB oversees the company’s therapeutic antibody pipeline, including antibody target identification and validation, second generation antibody formats, and selection of candidate therapeutic antibodies for preclinical development and clinical proof of concept studies. AIMM-therapeutics is currently expanding its programs in the areas of cancer and autoimmune- and inflammatory diseases.
Help employers find you! Check out all the jobs and post your resume.
